Alere India, a subsidiary of the US-based Alere Inc, held a two-day biomarker conclave from October 5 here to discuss the latest advances in the sector and deliberate the standards in clinical application of biomarker for early diagnosis.

Medical experts from all over India, including cardiologists, internists, primary care physicians, emergency medicine physicians, clinical laboratorians and nephrologists attended the 3rd edition of the Alere Biomarker Conclave.

The two-day annual event saw back-to-back sessions  on topics such as biomarkers in acute coronary syndromes, biomarkers in heart failure, and biomarkers of renal injury and failure. The second day saw a session on consensus formation.

The conclave empowered the participants to better utilize the current standards of care associated with the application of biomarkers in cardio-vascular disease, said Alan S. Maisel, Director, Coronary Care Unit and Heart Failure Program, VA San Diego Healthcare System:

“Biomarkers have come to occupy an important place in our diagnostic procedures. They not only improve diagnostic accuracy, but also provide information about the present disease state, thereby aiding clinicians in deciding how aggressively the disease needs to be treated.  The discussions focused on newer biomarkers and guidelines,” said Sanjeev Johar, CEO of Alere India.

Panelists at the event included the renowned Dr. Alan S Maisel as Chairman, with Dr. Brian Pinto, Director of Cardiology – Holy Family Cardiac Institute (Mumbai), and Dr. Jamshed J Dalal, Director – Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, co-chairing the event.